The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Cellular Classification

Added Parham et al. as reference 2.

Added Krsková et al. as reference 12.

Previously Untreated Childhood Rhabdomyosarcoma

Added text to state that COG has evaluated whether the addition of topotecan and cyclophosphamide to standard VAC therapy improves outcome for children with intermediate-risk rhabdomyosarcoma. The COG clinical trial (COG-D9802) showed that patients randomized to receive topotecan and cyclophosphamide fared no better than those treated with VAC alone.

Added text to state that high-risk patients have poor prognosis (≤50% five-year survival rate) with current therapy, and new approaches to treatment are needed.

Added text to state that the standard systemic therapy for children with metastatic rhabdomyosarcoma, is the three drug combination of vincristine, actinomycin-D, and cyclophosphamide (VAC). Clinical trails support this therapy.

Added text to state that high-dose chemotherapy with stem cell rescue (SCR) has been evaluated in a limited number of patients with rhabdomyosarcoma and show no benefit.

Added Magné et al as reference 91.

Back to Top

< Previous Section  |  Next Section >